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A B S T R A C T   
Glucocorticosteroids are the first-line therapy for controlling airway inflammation in asthma. They bind intra-
cellular glucocorticoid receptors to trigger increased expression of anti-inflammatory genes and suppression of 
pro-inflammatory gene activation in asthmatic airways. 
In the majority of asthma patients, inhaled glucocorticoids are clinically efficacious, improving lung function 
and preventing exacerbations. However, 5–10 % of the asthmatic population respond poorly to high dose inhaled 
and then systemic glucocorticoids. These patients form a category of severe asthma associated with poor quality 
of life, increased morbidity and mortality, and constitutes a major societal and health care burden. Inadequate 
therapeutic responses to glucocorticoid treatment is also reported in other inflammatory conditions such as 
rheumatoid arthritis and inflammatory bowel disease; however, asthma represents the most studied steroid- 
refractory disease. Several cellular and molecular events underlying glucocorticoid resistance in asthma have 
been identified involving abnormalities of glucocorticoid receptor signaling pathways. These events have been 
strongly related to immunological dysregulation, genetic, and environmental factors such as cigarette smoking or 
respiratory infections. A better understanding of the multiple mechanisms associated with glucocorticoid 
insensitivity in asthma phenotypes could improve quality of life for people with asthma but would also provide 
transferrable knowledge for other inflammatory diseases. In this review, we provide an update on the molecular 
mechanisms behind steroid-refractory asthma. Additionally, we discuss some therapeutic options for treating 
those asthmatic patients who respond poorly to glucocorticoid therapy.   
1. Introduction 
Glucocorticosteroids (GCs), also called glucocorticoids, corticoste-
roids or steroids, are natural regulators of a wide range of biological 
processes including the hypothalamic-pituitary-adrenal (HPA) axis, 
immunity and energy metabolism, primarily to maintain homeostasis. In 
humans, the hormone cortisol is the primary endogenous glucocorticoid, 
synthesized and secreted by the adrenal cortex. It interacts with the GC 
receptor (GR) to regulate a plethora of signaling pathways [1]. GCs are 
associated with potent anti-inflammatory activity, which can be 
exploited for therapeutic drug use. Synthetic GCs (e.g. prednisolone, 
dexamethasone) can be synthesized in bulk and designed for higher 
affinity binding to GR. They are used in medicine, to mimic this natural 
pathway of immune suppression and attenuate inappropriate inflam-
mation. They are the mainstream therapy for a wide range of acute and 
chronic inflammatory diseases, including asthma. The Global Initiative 
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for Asthma (GINA) defines asthma as “a heterogeneous disease that is 
characterized by chronic inflammation of the airways and a clinical 
history of wheezing, cough, tightness of chest and shortness of breath 
varying with time and intensity, as well as expiratory airflow limitation” 
(https://ginasthma.org/). Asthma affects over 300 million people 
worldwide, with increasing incidence. The heterogeneity of ‘asthma’ 
suggests it should be an umbrella term for different phenotypes. There 
are two recognizable endotypes: allergic asthma, driven by a T helper 
2-subset (T2-type) response, or non-allergic, non-atopic (non-T2) 
asthma, driven by other immune cells such as neutrophils [2–4]. GCs 
represent first-line treatment for asthma but there are two major limi-
tations: firstly, toxic high dose-dependent side effects and secondly the 
refractory response seen among asthma patients, predominantly those 
with severe disease. Early asthma studies, mostly in children, charac-
terized asthma as an IgE-dependent inflammatory response to allergens 
associated with eosinophilia [5]. This led to treatments centralized 
around inhibiting Th2 cytokines, and this delayed the recognition and 
understanding of non-T2 asthma phenotypes and hindered development 
of appropriate treatment options. T2 asthma is the dominant sub-group, 
and generally responds effectively to GC treatments. In contrast, non-T2 
severe asthma is associated with GC insensitivity. 
Herein we provide a state-of-the-art overview of the proposed 
mechanisms leading to glucocorticoid refractory asthma and potential 
therapeutic strategies. 
2. Mechanisms of action of glucocorticoids 
Although GCs have been widely used for many decades, the complete 
understanding of their multiple molecular mechanisms of immune 
modulation is still elusive. It is known that they act through genomic and 
nongenomic mechanisms. The strong suppression of airway inflamma-
tion is mainly due to the genomic mechanism. GCs act by binding to 
intracellular receptors of the target cell (glucocorticoid receptors; GRs). 
Genomic mechanisms derive from glucocorticoids binding to glucocor-
ticoid receptors in the cytoplasm and the translocation of the GC/GR 
complex into the nucleus. In the nucleus, the GC/GR complex modifies 
transcription of specific genes through direct DNA binding or tran-
scription factor inactivation (Fig. 1). This is either done by binding to 
small motifs known as GC response elements (GRE) in the promoter 
regions of susceptible genes. GRs consist of different subunits, with a 
variable N-terminal domain, C-terminal domain, and a DNA binding 
domain, with zinc fingers to assist genomic interactions. GRs are located 
in an inactive form in the cytoplasm, as a multi-protein complex, 
attached to a chaperone protein. Originally, upon activation, it was 
believed that the GR and chaperone protein dissociated allowing the GR 
to translocate into the nucleus. However, research now indicates that the 
chaperone complex is required for nuclear transportation [6]. The GR 
can function as a monomer, homo, or hetero-dimer, and recently 
described as a tetramer [7]. There are two variants of the receptor, GR-α, 
and GR-β, with subtle splicing differences in the C-terminal domain. The 
GR-β isoform is most abundantly expressed; however, it is unable to bind 
to GCs and therefore cannot transduce GC-induced functions. It is 
believed to regulate GC activity, through antagonizing the GR-α isoform 
and regulation through GR-α/β heterodimers [8,9]. GR-α is subject to 
different post-translational modifications, which include phosphoryla-
tion, acetylation and other modifications that affect GR signaling path-
ways [10]. 
Once inside the nucleus, the GC/GR complex functions by regulating 
up to 20 % of genes expressed by immune cells. Specifically, GCs act by 
trans-repressing inflammatory genes and stimulating the transcription 
of anti-inflammatory genes leading to reduced activation, recruitment 
and survival of inflammatory and epithelial cells [1,11,12]. Glucocor-
ticoids may also regulate the immunomodulatory function of smooth 
muscle cells and affect airway remodeling in asthma [13]. Other 
genomic mechanisms such as regulation of mRNA stability have been 
also described [14]. Nongenomic actions are mediated by specific 
interaction with membrane-bound or cytoplasmic GRs, or nonspecific 
interactions with the cell membrane [15]. 
Synthetic GCs are designed with optimal characteristics for potent, 
high affinity binding to the GR only, making them more specific than 
natural GC, which bind to both the GR and the closely related miner-
alocorticoid receptor [16,17]. GCs also possess pro-inflammatory ef-
fects, under stress conditions [18]. 
3. Glucocorticoid resistance 
The term glucocorticoid resistance is formally used to describe the 
resistance to adrenal suppression by dexamethasone, as in Cushing’s 
syndrome. In asthma, patients generally respond well to GCs, but in 
some this can vary and when responses to inhaled and then oral GCs are 
inadequate this is called steroid unresponsive, refractory or resistant 
asthma. According to international guidelines, for adults and children 
patients with persistent asthma low-dose inhaled corticosteroids (ICS) 
with or without long-acting bronchodilator (β2-agonists) represent the 
Fig. 1. Glucocorticoid transcriptional regulation. The lipid- 
soluble glucocorticoid (GC) passively diffuses through the 
cell membrane and binds to the glucocorticoid receptor (GR-α) 
in the cytoplasm. Once ligated the GC/GR complex translocate 
into the nucleus through the nuclear pore or exerts non- 
genomic effects in the cytoplasm. In the nucleus, the complex 
can either: 1. Bind directly to DNA and regulate transcription 
using positive GC response elements (GREs) or negative GREs; 
2. Interact with other transcription factors (TF) to mediate 
their activity or; 3. Compositely bind to both DNA and TFs to 
regulate gene transcription. Notably, all three of these mech-
anisms can positively and negatively regulate gene expression. 
Figure created in BioRender (https://biorender.com/).   
I. Henderson et al.                                                                                                                                                                                                                              
Pharmacological Research 160 (2020) 105189
3
first-line therapy. Besides, they are recommended in patients with 
intermittent or mild asthma requiring a short-acting β2-agonist more 
than twice a week or twice a month (https://ginasthma.org/). 
For the majority of asthma patients, ICS work well, improving lung 
function and reducing exacerbations. Patients with difficult asthma 
require higher doses of oral GCs to manage their asthma, and these 
include 5–10 % of patients who don’t respond satisfactorily to these 
drugs, resulting in difficult to manage asthmatic symptoms thus denoted 
as having steroid-resistant asthma [19]. Th2-low asthma phenotypes are 
less responsive to steroid therapies and have a higher prevalence of se-
vere asthma cases. However, glucocorticoid insensitivity in patients 
with persistent eosinophil inflammation has also been described [20]. 
They are a disproportionately large burden on health care; the 10 % with 
refractory asthma cost 80 % of health care costs [21], along with a 
significantly increased morbidity and mortality [22]. This emphasize 
the importance of a better understanding of this poor responsiveness and 
the need for new therapeutic options. 
Steroid resistance is defined as <15 % improvements in forced 
expiratory volume in 1 s (FEV1), after 2 weeks of appropriate dose ste-
roid treatment. These patients, however, do respond well to β2-adren-
ergic agonist-mediated vasodilation [23,24]. There are currently no 
clinically accepted biomarkers or phenotypes for resistance; meaning 
diagnosis is based on the clinical history and lung function after suffi-
cient steroid treatments. This results in patients receiving increasing 
doses of steroids for extended periods, until it is recognized that this is 
ineffective for treating the severity of asthma. Indeed, a key cause of 
morbidity in these patients comes from the toxic side effects of long-term 
high-dose steroids; these include increased susceptibility to infections, 
osteoporosis, hyperglycemia and cardiovascular disease [25,26]. 
3.1. Understanding mechanisms of the inadequate responses to 
glucocorticosteroids 
To gain a better understanding of steroid resistance an important 
distinction must be made between patients who poorly manage their 
asthma and the group of genuinely refractory asthmatic patients. Several 
studies highlighted that about one third of difficult asthma cases that did 
not respond to CS was due to poor compliance and not steroid insensi-
tivity [27,28]. The clinical pattern of exacerbations and poor asthma 
control was similar to the GC-refractory patients. Fortunately, 
poor-compliance can be assessed by measuring fractional exhaled nitric 
oxide (FENO) levels which is high in asthma and is reduced confirming 
compliance with steroid treatment unless the patient is bluntly resistant 
to the treatment [29]. 
Successful adherence to medications is a complex issue, with many 
patients either self-assessing their condition and coming off long-term 
treatments when they feel healthy or become overly concerned about 
the side effects of the treatments. Another major issue is poor inhalation 
technique, considered non-intentional non-adherence [30], which can 
be resolved with better training. Once the true refractory patient cohort 
is identified studies can be more accurate, focusing on the causes of 
insensitivity and alternative therapeutic interventions. 
Refractory patients have typically severe asthma, with low percent- 
predicted FEV1 indicating higher levels of fixed airway obstruction 
and reduced lung function [31,32]. A consideration here is whether the 
lack of efficacy of GCs results in severe symptoms or whether the in-
flammatory mechanisms maintaining severity also drives resistance. 
3.2. Cellular and molecular basis of glucocorticoid-resistance 
Poor steroid responsiveness can be inherited or acquired. Inherited 
genetic mutations specifically associated with refractory asthma remain 
poorly described [33]. Many genomic wide association studies (GWAS) 
and pharmacogenomic studies have been carried out to investigate the 
relationship between genetic variations and response to steroids. 
High-density oligonucleotide microarray studies of peripheral blood 
mononuclear cells (PBMCs) from patients with glucocorticoid-sensitive 
asthma and those with glucocorticoid-resistant asthma revealed that 
11 genes accurately predicted corticosteroid resistant asthma [34]. 
Further pharmacogenomic studies including an appropriately large pa-
tient cohort would be useful to power a study to fully differentiate 
glucocorticoid-resistant and glucocorticoid-sensitive asthmatic patients. 
Single nucleotide polymorphisms in the GLCCI1 gene, encoding the 
glucocorticoid-induced transcript 1 protein, were associated with 
response to GC therapy in asthma [35]. These findings were replicated in 
multiple candidate gene analysis studies [36,37]. The functional single 
nucleotide polymorphism, rs37973, was associated with reduced ICS 
sensitivity. Children with two copies of the mutant allele are less 
responsive to GC therapy [35], and increased expression of GLCCI1 
demonstrated better responses to ICS [38]. Several additional genes 
have significant associations with GC insensitivity. However, these 
finding were not well replicated between studies, perhaps due to vari-
ation in protocols, heterogeneity of asthma phenotype, or the 
complexity of the GC pathways. It is feasible that GC insensitivity is not 
caused by a singular mutation, and more likely involves a range of ge-
netic variations that remain to be determined. 
Multiple molecular mechanisms have been identified associated with 
GC dysfunction including: reduced GR-α expression [39], defective 
binding between the GC and the GR or between the GR complex and 
DNA [40], and increased antagonism, either from increased 
pro-inflammatory transcription factors or increased GR-β expression 
[41]. Additionally, GR phosphorylation by e.g. p38 mitogen-activated 
protein kinase (MAPK) and by reduced activity of histone deacetylase 
2 (HDAC2) can reduce the expression various anti-inflammatory genes 
induced by GCs [42,43]. 
As examples of acquired GC resistance, inflammation or oxidative 
stress can negatively affect GR signaling [22] Possible mechanisms for 
acquired resistance could be related to immune dysregulation; for 
example, interleukin (IL)-2, IL-4 and IL-13 are often overexpressed in the 
lungs of steroid insensitive patients [44–46]. This profile of cytokine 
up-regulation is associated with reduced GR affinity in vitro through 
activation of p38 mitogen-activated protein kinase resulting in the 
phosphorylation of GR and diminished nuclear translocation in in-
flammatory cells [47]. 
Th1 cytokines have also been associated with GC-resistance. Spe-
cifically, IFN-γ can increase GR phosphorylation and inhibit GR nuclear 
translocation in different experimental models of steroid-resistant 
airway hyperresponsiveness by up-regulating miR-9 expression in the 
lung and pulmonary macrophages [48]. Recently, TNF-α and IFN-γ cy-
tokines have been shown to sustain glucocorticoid-resistance in human 
fetal airway smooth muscle cells by promoting the Nuclear factor-κB 
(NF-κB) pathway and Stat1 phosphorylation [49]. 
Kim and co-workers have suggested that in murine models of steroid- 
resistant allergic airway disease, the exaggerated NLR Family Pyrin 
Domain Containing 3 (NLRP3) inflammasome/IL-1β activation critically 
contributed to glucocorticoid resistance [50]. The mechanism is not yet 
fully understood but included a role for IL-1β in Th17 cell differentiation 
and IL-17 production [51]. It is interesting to note that asthmatic pa-
tients resistant to glucocorticoids show increased Th17 cells and IL-17A 
levels [52], and the adoptive transfer of Th17 cells in mice has resulted 
in the development of steroid insensitivity [53]. Accordingly, Th17 re-
sponses have been shown to increase the expression of GR-β, a mecha-
nism of steroid resistance in bronchial epithelial cells [54]. Very 
recently, Ouyang et al. have found that IL-17A synergizes with dexa-
methasone in inducing colony-stimulating factor 3 (CSF 3) in both 
human airway smooth muscle cells and fibroblasts through transcrip-
tional and post-transcriptional regulation. This effect is further 
increased in the presence of TNF-α, as described above, and has been 
associated with glucocorticoid resistance [55]. Additionally, it has been 
suggested that IL-17 produced in the lung by type 3 innate lymphoid 
cells, ILC3, may play a role in steroid resistance associated with the 
obesity phenotype of asthma [56]. 
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GC insensitivity has been associated with dysregulated IL-10 pro-
duction. Specifically, T lymphocytes from corticosteroid-resistant asth-
matic patients have impaired IL-10 production following in vitro 
stimulation with dexamethasone compared to T lymphocytes from 
steroid-sensitive asthmatics [57]. This defect can be reversed by the 
combination of GC with salmeterol or the administration of vitamin D3 
[58,59]. Recently, a decreased regulatory T-cell activity has been shown 
in older asthmatic patients that render them more vulnerable to type 2 
inflammation and steroid resistance [60]; thereby, suggesting age as an 
important factor in determining glucocorticoid sensitivity. 
Exogenous factors such as cigarette smoking, respiratory viral and 
bacterial infections, high-fat diet and/or obesity, may also contribute to 
mechanisms of steroid-resistant asthma. The airway inflammation 
observed in asthma patients who smoke cigarettes is typically neutro-
philic rather than eosinophilic. This non-T2 endotype is consistent with 
the major phenotypes of steroid-refractory asthma. A mechanism pro-
posed for cigarette smoke induced GC-insensitivity is a reduced ratio of 
GR-α to GR-β isoforms [61], resulting in increased antagonism of the 
GR-α. Cigarette smoke is associated with reduced HDAC activity in 
alveolar macrophages, which controls access to chromatin, a crucial 
stage in GC-mediated gene regulation [62,63]. This could be a potential 
target for novel therapies, to re-balance the isotype ratio and increase 
HDAC activity to re-sensitize patients to steroids. An additional mech-
anism included the ligation by cigarette smoke components of the aryl 
hydrocarbon receptor that suppresses smoke-induced inflammation, 
apoptosis and oxidative stress. It is proposed this is done through 
microRNA regulation inhibiting protein synthesis [64] and indirectly 
regulating the Th17 pathways, which have been linked with steroid 
resistance, as discussed above. Th17 cells mediate neutrophilic airway 
inflammation by stimulating the production of IL-8. McSharry et al. have 
shown the increase in neutrophils and IL-8 levels in sputum fluid from 
asthmatic smokers compared to that from nonsmokers with asthma, 
suggesting a contribution for this cytokine in glucocorticoid insensitivity 
[65]. Another clinically important study has shown that steroid sensi-
tivity returns after smoking cessation suggesting mechanisms of resis-
tance are reversible [66] and providing smoking cessation advice as a 
clear therapeutic strategy. 
Exposure to combustion products from cigarette smoke or burning 
biomass fuel is a major cause of the development of chronic obstructive 
pulmonary disease (COPD). COPD is stubbornly refractory to mainstay 
corticosteroid treatment and the molecular mechanisms of steroid 
insensitivity in COPD are incompletely understood [67]. Similar to 
asthma in cigarette smokers, it has been proposed that cigarette smoke 
and oxidative stress in COPD may decrease HDAC2 activity [22] and 
increase various kinase pathways such as p38 MAPK [68]. Of note, the 
lung inflammation in COPD and smokers with asthma is predominantly 
neutrophilic [69], and is the basis of defining an asthma− COPD overlap 
syndrome (ACOS) sharing steroid-refractory Th17 endotype that pre-
disposes to neutrophilia and neutrophilic asthma is associated to steroid 
resistance [70,71]. 
A role for viral and/or bacterial respiratory infections in glucocor-
ticoid refractivity in asthmatic patients has been also described. Spe-
cifically, Chlamydia pneumoniae, Haemophilus influenzae, rhinovirus, 
influenza A virus (IAV) and respiratory syncytial virus (RSV) infections 
have each been associated with steroid resistance [72–76]. The reduc-
tion of GR-α nuclear translocation through NF-κB and c-Jun N-terminal 
kinase activation has been proposed as a molecular mechanism of 
glucocorticoid insensitivity in rhinovirus-infected primary human 
bronchial epithelial cells [77]. 
Non-T, neutrophilic asthma patients often have bacterial infections, 
which could impair steroid sensitivity [78]. Some bacterial products, 
such as staphylococcal endotoxins B, have been shown to increase GR-β 
expression [79]. Recently, Kim et al. have developed novel mouse 
models of steroid-resistant asthma driven by bacterial (Chlamydia and 
Haemophilus influenzae) and viral (influenza and RSV) respiratory tract 
infections. In these experimental models, the authors demonstrated a 
role for miR-21 in inducing steroid insensitivity through PI3K-mediated 
phosphorylation and nuclear translocation of pAKT [80]. 
Steroid resistance has been also associated with fungus-exposed pa-
tients through induction of Th2/Th17 responses [81]. Also Aspergillus 
alternata exposure has been shown to induce IL-33 dependent 
steroid-resistant asthma, mediated by ILC2 and Th2 cells in neonatal 
mice [82]. It has been suggested that the ability of IL-33 to activate 
p38-MAPK in CD4 + T cells and to induce phosphorylation of GR may be 
a mechanism underlying glucocorticoid insensitivity [83]. 
As described above, GCs can exert also non-genomic actions, espe-
cially at high concentrations, and few non-genomic pathways have been 
identified to date. GCs can inhibit the degranulation of mast cells 
through stabilization of the plasma membrane or by a reduction in 
[Ca2+] elevation [84]. In addition, GCs can exert their 
anti-inflammatory effects by negative interference with MAPK signaling 
pathways [85]. Abnormalities of these non-genomic mechanisms on 
immune cells may contribute to GC insensitivity; however, more 
research is needed to fully understand how non-genomic mechanisms 
can influence GC sensitivity. 
Key molecular mechanisms involved in steroid resistance in asth-
matic patients are summarized in Table 1 and Fig. 2. 
3.3. Therapeutic perspectives 
From the information provided, and the little progress in the past 
decades towards effective treatments for non-T2, steroid-refractory 
asthma, it is clear that future research needs a multidisciplinary 
approach and knowledge collaborations to reach a deeper understand-
ing of steroid insensitivity. Some of the main molecular mechanisms 
have been identified; however, a deeper understanding of these mech-
anisms is needed before pharmacogenomic data can be clinically uti-
lized in predicting drug responses and effectively optimizing treatments. 
Innovative solutions should consider environmental and genetic 
factors contributing to the resistance, better technologies for molecular 
imaging of inflammation [87], and, in the era of big data, the estab-
lishment of large databases to support immune research into drug dis-
covery and therapeutics [88,89], along with omics approaches for the 
identification of biomarkers. Several serum biomarkers have been pro-
posed to predict steroid resistance in asthmatic children such as vitamin 
D-binding protein (VDBP), miRNA-21 and OX40 ligand [90–93]. 
The development of more personalized approaches for steroid- 
resistant asthma is particularly useful because of the different mecha-
nisms and multiple immunological and inflammatory phenotypes likely 
leading to steroid resistance. Traditionally steroids were considered a 
universal treatment, with reduced sensitivity forcing a higher dose 
regime, following the theory that stronger Th2 responses require higher 
doses of steroid suppression. It is now evident that complex asthma 
phenotypes highlight the need for patient stratification and individual-
ized therapy. 
Identifying the underlying endotype driving each phenotype should 
Table 1 
Proposed molecular mechanisms of steroid resistance.  
Mechanism References 
Genetic abnormalities in GRs [83] 
Reduced GR-α expression [39] 
Defective GC binding to GR-α [40] 
Reduced GR-α translocation due to increase phosphorylation by 
kinases such as p38 MAPK and JNK 
[43] 
Reduced HDAC2 activity and expression [42] 
Increased pro-inflammatory transcription factor activation, such as NF- 
kB and AP1 
[41] 
Increased GR-β expression [86] 
Abbreviations: GR: glucocorticoid receptor, GC: glucocorticoid, MAPK: mitogen- 
activated protein kinase, JNK: c-Jun N-terminal kinase, HDAC: histone deace-
tylase, NF-KB: nuclear factor-κB, AP1: activator protein-1. 
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be utilized when considering the optimal treatments. This requires 
multidisciplinary collaborations to identify the different aspects of 
insensitivity. Once a better understanding is gained optimal treatments, 
such as biologicals, can be used instead of non-specific 
immunosuppressants. 
Better education should also be provided on steroid functions and 
inhaler technique, to limit the non-adherence patients. Most steroid- 
resistant research is done on asthma; however, similar insensitivity is 
observed, with more frequent rates, in other inflammatory respiratory 
diseases such as chronic obstructive pulmonary disease, and in rheu-
matoid arthritis, and inflammatory bowel disease [94,95]. A better 
understanding of multiple mechanisms associated with GC insensitivity 
in asthma could provide transferrable knowledge for other inflamma-
tory diseases since similar molecular mechanisms have been proposed. 
To attain more accurate research a new disease model is required, to 
fully understand the mechanisms, as well as identifying biomarkers to 
use for early identification and screening for insensitivity. This will help 
alleviate the time lost trialing different steroid doses, as well as opti-
mally treating the patient. 
Most clinical trials to validate new therapeutics for asthma typically 
exclude smokers. Since steroid insensitivity is prominent in smokers 
[96], future clinical trial studies should include this category of asthma 
patients. 
Therapeutic target for reversing steroid insensitivity could include 
blocking the underlying mechanisms e.g. with antibodies against the key 
cytokines such as IL-17, IL-8, and TNF-α associated with the neutrophilic 
airway inflammation that is strongly steroid-resistant. Regarding NLRP3 
inflammasome/IL-1β, it has been demonstrated that specific inhibition 
of the NLRP3 inflammasome is more advantageous than global inhibi-
tion of IL-1β [79]. 
Interestingly, the combined use of different drugs can restore 
glucocorticoid sensitivity. Steroid-resistance in asthma has been asso-
ciated with imbalanced acetylation and deacetylation of GRs variously 
regulating gene transcription. Increased HDAC activity using theophyl-
line, PI3K and p38 MAPK inhibitors [96–98] may be beneficial, espe-
cially in glucocorticoid resistant asthmatic smokers. Combined therapy 
with long-acting beta 2 agonists has improved glucocorticoid responses 
by affecting GR translocation and phosphorylation. This therapeutic 
strategy and could be useful for asthmatic patients in whom a poor 
response is related to abnormal GR signaling [99,100]. Other studies 
suggest that macrolides such as azithromycin and clarithromycin 
potentiate glucocorticoid sensitivity in asthma, but the mechanism 
remains unclear [101–103]. Another interesting study has shown that 
statins increase the anti-inflammatory effect of glucocorticoid though 
induction of indoleamine 2, 3-dioxygenase in alveolar macrophages 
[104]. A combination of these different therapeutic strategies may help 
to effectively reduce GC resistance. 
Finally, recent new highly potent glucocorticoids have been devel-
oped for steroid-resistant severe asthma. Among them, only GCVSG158 
was demonstrated to reverse steroid-resistance in a murine model of 
eosinophilic and neutrophilic airway inflammation [105]. 
4. Conclusions 
In conclusion, although glucocorticoid resistance is observed in a 
small proportion of asthmatic patients, it represents a serious clinical 
and socioeconomic problem. Therefore, future research on the molec-
ular mechanisms of multiple steroid-resistant asthma endotypes and the 
identification of subgroups of patients with poor responses to steroids 
will facilitate the selection of appropriate treatment, in a stratified 
fashion for those phenotypes and the development of novel therapeutic 
approaches. 
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